<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-8909</journal-id>
<journal-title><![CDATA[Medicina crítica (Colegio Mexicano de Medicina Crítica)]]></journal-title>
<abbrev-journal-title><![CDATA[Med. crít. (Col. Mex. Med. Crít.)]]></abbrev-journal-title>
<issn>2448-8909</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Medicina Crítica A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-89092024000600473</article-id>
<article-id pub-id-type="doi">10.35366/119235</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Asociación de haptoglobina sérica como predictor de mortalidad en los pacientes críticos con hemorragia subaracnoidea aneurismática]]></article-title>
<article-title xml:lang="en"><![CDATA[Association of serum haptoglobin as a predictor of mortality in critically ill patients with aneurysmal subarachnoid hemorrhage]]></article-title>
<article-title xml:lang="pt"><![CDATA[Associação da haptoglobina serica como preditor de mortalidade em pacientes em estado crítico com hemorragia subaracnoidea aneurismática]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mogollón Martínez]]></surname>
<given-names><![CDATA[Edgar Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jiménez Correa]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González Carrillo]]></surname>
<given-names><![CDATA[Pedro Luis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez González]]></surname>
<given-names><![CDATA[Ma. Natalia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Hospital Especialidades No. 1 del Centro Médico Nacional del Bajío Unidad Médica de Alta Especialidad]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<volume>38</volume>
<numero>6</numero>
<fpage>473</fpage>
<lpage>477</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-89092024000600473&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-89092024000600473&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-89092024000600473&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  La identificación de los niveles séricos de haptoglobina se ha mencionado como un factor relacionado en la enfermedad cerebral vascular de origen aneurismático, y puede contribuir al aumento de las complicaciones. Es una proteína sintetizada por el hígado que se une a la hemoglobina libre después de la lisis de los glóbulos rojos y, al hacerlo, previene la toxicidad inducida por la hemoglobina y facilita la eliminación. Los estudios clínicos en pacientes con hemorragia subaracnoidea indican que los sujetos con niveles alterados de haptoglobina pueden ser un grupo de alto riesgo de complicaciones relacionadas con la hemorragia y malos resultados en la mortalidad.  Objetivo:  Determinar la asociación de los niveles de haptoglobina sérica son predictores de mortalidad en hemorragia subaracnoidea aneurismática en la Unidad de Cuidados Intensivo del Centro Médico Nacional Bajío.  Material y métodos:  Estudio observacional, descriptivo, longitudinal, analítico. Realizado del 1 de marzo al 21 de agosto de 2024 en pacientes que ingresaron a la Unidad de Cuidados Intensivos con hemorragia subaracnoidea aneurismática (HSAa). Mediante un muestreo a conveniencia no probabilístico se registraron los valores de haptoglobina sérica (HAPT 2), y la sobrevivencia de los pacientes incluidos. La haptoglobina se relacionó como predictor de mortalidad.  Resultados:  Se incluyeron 27 pacientes que cumplieron con los criterios de selección, 17 mujeres (63%), con edad media de 51.48 ± 15.05; se registró antecedente de hipertensión arterial sistémica en 13 (48.1%) pacientes y diabetes mellitus tipo 2 en cinco (18.5%). El neuromonitoreo con ultrasonido Doppler reportó una presión intracraneal de 21.03 ± 4.01, hipertensión intracraneana en seis (22.2%); la haptoglobina sérica (Hapt 2) fue de 167.68 ± 110.4 mg/dL. Se detectó vasoespasmo en siete (25.9%) de los pacientes. No sobrevivieron ocho (29.6%) pacientes. El promedio de días de supervivencia de la población fue de 109.04 ± 140.24. El análisis de ROC con una AUC de 0.836 (p = 0.007) IC95% (0.680-0.991).  Conclusión:  En pacientes con HSAa se sugiere utilizar los niveles de haptoglobina sérica como predictor de mortalidad.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  The identification of serum haptoglobin levels has been mentioned as a related factor in cerebral vascular disease of aneurysmal origin, and may contribute to increased complications. It is a protein synthesized by the liver that binds to free hemoglobin after lysis of red blood cells and, in doing so, prevents hemoglobin-induced toxicity and facilitates clearance. Clinical studies in patients with subarachnoid hemorrhage indicate that patients with altered haptoglobin levels may be a high-risk group for bleeding-related complications and poor mortality outcomes.  Objective:  To determine the association of serum haptoglobin levels are predictors of mortality in aneurysmal subarachnoid hemorrhage in the Intensive Care Unit of the Bajío National Medical Center.  Material and methods:  Observational, descriptive, longitudinal, analytical study. Conducted from March 1 to August 21, 2024 in patients admitted to the Intensive Care Unit with aneurysmal subarachnoid hemorrhage (aSAH). Serum haptoglobin values (HAPT 2) and survival of the included patients were recorded by means of non-probabilistic convenience sampling. Haptoglobin was related as a predictor of mortality.  Results:  Twenty-seven patients who met the selection criteria were included, 17 women (63%), with a mean age of 51.48 ± 15.05, a history of systemic arterial hypertension was recorded in 13 (48.1%) and type 2 diabetes mellitus in five (18.5%) patients. Neuromonitoring with Doppler ultrasound reported ICP of 21.03 ± 4.01, ICH (intracranial hypertension) in six (22.2%); serum haptoglobin (Hapt 2) was 167.68 ± 110.4 mg/dL. Vasospasm was detected in seven (25.9%) of the patients. Not survived eight (29.6%) patients, and the mean population survival days was 109.04 ± 140.24. ROC analysis with an AUC of 0.836 (p = 0.007) 95%CI (0.680-0.991).  Conclusion:  In patients with aSAH we suggest using serum haptoglobin levels as a predictor of mortality.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  A identificação dos níveis séricos de haptoglobina foi mencionada como um fator relacionado à doença vascular cerebral de origem aneurismática e pode contribuir para o aumento das complicações. É uma proteína sintetizada pelo fígado que se liga à hemoglobina livre após a lise dos glóbulos vermelhos e, dessa forma, evita a toxicidade induzida pela hemoglobina e facilita a eliminação. Estudos clínicos em pacientes com hemorragia subaracnóidea indicam que os pacientes com níveis alterados de haptoglobina podem ser um grupo de alto risco para complicações relacionadas à hemorragia e resultados ruins de mortalidade.  Objetivo:  Determinar a associação dos níveis séricos de haptoglobina como preditores de mortalidade em hemorragia subaracnóidea aneurismática na UTI do CMN Bajío.  Material e métodos:  Estudo observacional, descritivo, longitudinal e analítico. Realizado de 1o de março a 21 de agosto de 2024 em pacientes internados na Unidade de Terapia Intensiva (UTI) com HSAa. Utilizando amostragem não probabilística de conveniência, foram registrados os valores séricos de haptoglobina (HAPT 2) e a sobrevida dos pacientes incluídos. A haptoglobina foi relacionada como preditor de mortalidade.  Resultados:  Vinte e sete pacientes que atenderam aos critérios de seleção foram incluídos, 17 mulheres (63%), com idade média de 51.48 ± 15.05, um histórico de HAS foi registrado em 13 (48.1%) e DM2 em 5 pacientes (18.5%). O neuromonitoramento por ultrassom Doppler relatou PIC de 21.03 ± 4.01, HIC (hipertensão intracraniana) em 6 (22.2%); a haptoglobina sérica (Hapt 2) foi de 167.68 ± 110.4 mg/dL. Vasoespasmo foi detectado em 7 (25.9%) pacientes. Oito (29.6%) pacientes não sobreviveram e a média de dias de sobrevivência da população foi de 109.04 ± 140.24. Análise ROC com uma AUC de 0.836 (p = 0.007) IC95% (0.680-0.991).  Conclusão:  Em pacientes com HSAa, sugere-se o uso dos níveis de haptoglobina sérica como um preditor de mortalidade.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[hemorragia subaracnoidea aneurismática]]></kwd>
<kwd lng="es"><![CDATA[haptoglobina sérica]]></kwd>
<kwd lng="es"><![CDATA[mortalidad]]></kwd>
<kwd lng="es"><![CDATA[UCI]]></kwd>
<kwd lng="en"><![CDATA[aneurysmal subarachnoid hemorrhage]]></kwd>
<kwd lng="en"><![CDATA[serum haptoglobin]]></kwd>
<kwd lng="en"><![CDATA[mortality]]></kwd>
<kwd lng="en"><![CDATA[ICU]]></kwd>
<kwd lng="pt"><![CDATA[hemorragia subaracnóidea aneurismática]]></kwd>
<kwd lng="pt"><![CDATA[haptoglobina sérica]]></kwd>
<kwd lng="pt"><![CDATA[mortalidade]]></kwd>
<kwd lng="pt"><![CDATA[UTI]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neifert]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[EK]]></given-names>
</name>
<name>
<surname><![CDATA[Martini]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Shuman]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Schupper]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Oermann]]></surname>
<given-names><![CDATA[EK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aneurysmal subarachnoid hemorrhage: the last decade]]></article-title>
<source><![CDATA[Transl Stroke Res]]></source>
<year>2021</year>
<volume>12</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>428-46</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoh]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Ko]]></surname>
<given-names><![CDATA[NU]]></given-names>
</name>
<name>
<surname><![CDATA[Amin-Hanjani]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chou SH-]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz-Flores]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dangayach]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2023 Guideline for the management of patients with aneurysmal subarachnoid hemorrhage: a guideline from the American Heart Association/American Stroke Association]]></article-title>
<source><![CDATA[Stroke]]></source>
<year>2023</year>
<volume>54</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>e314-70</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hugelshofer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sikorski]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Seule]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Deuel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Muroi]]></surname>
<given-names><![CDATA[CI]]></given-names>
</name>
<name>
<surname><![CDATA[Seboek]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cell-free oxyhemoglobin in cerebrospinal fluid after aneurysmal subarachnoid hemorrhage: biomarker and potential therapeutic target]]></article-title>
<source><![CDATA[World Neurosurg]]></source>
<year>2018</year>
<volume>120</volume>
<page-range>e660-6</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Torvund-Jensen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nielsen]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[de Oliveira]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Hersleth]]></surname>
<given-names><![CDATA[HP]]></given-names>
</name>
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[NH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Structure of the haptoglobin-haemoglobin complex]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2012</year>
<volume>489</volume>
<numero>7416</numero>
<issue>7416</issue>
<page-range>456-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kazmi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Koda]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ndiaye]]></surname>
<given-names><![CDATA[NC]]></given-names>
</name>
<name>
<surname><![CDATA[Visvikis-Siest]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Morton]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gaunt]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetic determinants of circulating haptoglobin concentration]]></article-title>
<source><![CDATA[Clin Chim Acta]]></source>
<year>2019</year>
<volume>494</volume>
<page-range>138-42</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murthy]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Duckworth]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Schneider]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
<name>
<surname><![CDATA[Shalom]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hanley]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Presence of haptoglobin-2 allele is associated with worse functional outcomes after spontaneous intracerebral hemorrhage]]></article-title>
<source><![CDATA[World Neurosurg]]></source>
<year>2015</year>
<volume>83</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>583-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inflammation and oxidative stress: potential targets for improving prognosis after subarachnoid hemorrhage]]></article-title>
<source><![CDATA[Front Cell Neurosci]]></source>
<year>2021</year>
<volume>15</volume>
<page-range>739506</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Osgood]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aneurysmal subarachnoid hemorrhage: review of the pathophysiology and management strategies]]></article-title>
<source><![CDATA[Curr Neurol Neurosci Rep]]></source>
<year>2021</year>
<volume>21</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>50</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muehlschlegel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Subarachnoid hemorrhage]]></article-title>
<source><![CDATA[Continuum (Minneap Minn)]]></source>
<year>2018</year>
<volume>24</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1623-57</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Okazaki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kuroda]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aneurysmal subarachnoid hemorrhage: intensive care for improving neurological outcome]]></article-title>
<source><![CDATA[J Intensive Care]]></source>
<year>2018</year>
<volume>6</volume>
<page-range>28</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
